1. Glaucocalyxin A (Leukamenin F)-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. 2. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. 3. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. 4. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. 5. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.

M109S is a novel small molecule that shields cells from mitochondria-dependent apoptosis, demonstrating effectiveness both in vitro and in vivo. It shows promise as a research tool for probing cell death mechanisms and could lead to the development of therapeutics that target the mitochondria-dependent cell death pathway. M109S possesses oral bioactivity and excellent brain permeability [1].

Sarglaroids F (compound 6), an anti-inflammatory agent extracted from the roots of Grass Coral, suppresses LPS/ATP-induced IL-1β secretion by modulating K+ efflux and diminishing Caspase-1(P20) concentrations. Additionally, Sarglaroids F exhibits no cytotoxic effects on RAW264.7 cells [1].

Ferruginol has anti-plasmodial, leishmanicidal, anti-ulcerogenic, cardioprotective, anticancer, anti-oxidative and anti-inflammatory activities, it can induce apoptosis in non-small cell lung cancer (NSCLC) cells.

5,7,4'-Trimethoxyflavone (4',5,7-Trimethoxyflavone) is isolated from Kaempferia parviflora (KP) which is a medicinal plant from Thailand.